Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2025 Jan-Feb;26(1-2):2-21.
doi: 10.1111/1751-2980.13337. Epub 2025 Apr 8.

Chinese Guideline for the Diagnosis and Management of Drug-Induced Liver Injury in Primary Care (2024)

Collaborators, Affiliations
Practice Guideline

Chinese Guideline for the Diagnosis and Management of Drug-Induced Liver Injury in Primary Care (2024)

Yi Min Mao et al. J Dig Dis. 2025 Jan-Feb.

Abstract

Drug-induced liver injury (DILI) is a drug-induced disease that not only complicates the treatment of the primary disease but may also lead to acute liver failure or even death in severe cases. Drugs commonly used in primary care, such as anti-infective agents and nonsteroidal anti-inflammatory drugs, are major causes of DILI. In addition, a large elderly population, comorbidities, and combination therapy with multiple drugs increase the risk of DILI in primary care. Therefore, primary care providers should proactively screen and monitor high-risk patients to identify potential DILI timely. Currently, diagnosis of DILI relies on the exclusion of liver diseases of other etiologies. Collection of detailed medical history of the patients and careful exclusion of other potential liver injury of other etiologies are crucial for accurate diagnosis. This guideline, developed based on evidence-based medicine from the latest research, aimed to provide primary care providers with professional guidance on the timely identification of suspected DILI cases and standardized diagnosis and management in clinical practice.

Keywords: diagnosis; drug‐induced liver injury; guidelines; primary care; treatment.

PubMed Disclaimer

References

    1. Technology Committee on DILI Prevention and Management, Chinese Medical Biotechnology Association; Study Group of Drug‐Induced Liver Disease, Chinese Medical Association for the Study of Liver Diseases, “Chinese Guideline for Diagnosis and Management of Drug‐Induced Liver Injury (2023 Version),” Chinese Journal of Hepatology 31, no. 4 (2023): 355–384. [in Chinese].
    1. OCEBM Levels of Evidence Working Group, “The Oxford 2011 Levels of Evidence,” accessed April 2, 2024, https://www.cebm.ox.ac.uk/files/levels‐of‐evidence/cebm‐levels‐of‐eviden....
    1. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, “LiverTox: Clinical and Research Information on Drug‐Induced Liver Injury,” (2012) accessed April 2, 2024, https://www.ncbi.nlm.nih.gov/books/NBK547852/.
    1. Y. M. Mao, “HepaTox: Professional Network Platform for Promoting Clinical and Translational Research on Drug‐Induced Liver Injury in China,” Chinese Hepatology 19, no. 8 (2014): 575–576. [in Chinese].
    1. H. Devarbhavi, R. Dierkhising, W. K. Kremers, M. S. Sandeep, D. Karanth, and C. K. Adarsh, “Single‐Center Experience With Drug‐Induced Liver Injury From India: Causes, Outcome, Prognosis, and Predictors of Mortality,” American Journal of Gastroenterology 105, no. 11 (2010): 2396–2404.

Publication types

MeSH terms

Substances

LinkOut - more resources